Abbott said that an ongoing multisite clinical study indicated that its rapid COVID-19 test was accurate when detecting the virus nearly 95% of the time. Abbott said that an ongoing multisite ...

Abbott Laboratories shares were down Wednesdsay morning after the company laid out guidance for the first quarter of the year that was below market expectations.The stock was down 0.2% Wednesday while ...

The rapid tests are produced by Abbott Labs and are called the BinaxNOW COVID-19 Ag Card. There was a prior Abbott rapid test called the ID Now, which had been criticised in some studies for an ...

Fourth-quarter sales were $10.97 billion, Abbott said, in line with the $11 billion that Wall Street projected. Adjusted earnings in the quarter were $1.34 a share, meeting the average analyst ...

Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests. Guidance: Abbott projects full-year 2025 ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business ...